drugset / Trial / NCT00560560
Study Using CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer Treatments
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will test if there is any survival benefit in patients with refractory metastatic colorectal cancer that receive CP-751, 871.
Timeline
- Start
- 2007-12
- Primary completion
- 2010-09
- Completion
- 2010-09
Outcome
Missed primary endpoint
registry p >0.05; Test of probability of 6 month survival NCT00560560 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Figitumumab | Monoclonal antibody | 20 mg/kg | — |
| Subject | Figitumumab | Monoclonal antibody | 30 mg/kg | — |